247P Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study

Abstract

RIBECCA was a phase 3b, multicentre, open-label study of RIB + LET in patients (pts) of any menopausal status with HR+, HER2–ABC, who were not amenable to curative treatment (tx). The study investigated RIB + LET in pt settings broader than those considered in MONALEESA (ML) studies. Data on primary endpoint, clinical benefit rate (CBR) at week 24 in cohorts A (tx naive postmenopausal pts) and B (comprising cohort B1 [tx naive pre- and perimenopausal pts] and B2 [pre-, peri- and postmenopausal pts pretreated with ≤1 prior chemotherapy and ≤2 lines of endocrine therapy]) were reported previously.